secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-06-05T11:05:17+00:00
Accession:  0001193125-26-258366
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres receives $25M milestone buyout from Nestlé; restructures lease to cut costs, extends cash runway into Q1 2027
--------------------------------------------------------------------------------

- Nestlé Health Science pays $25M in two $12.5M installments (July & Oct 2026) to buy out future VOWST sales milestones.
- Lease amendment reduces space from 82,714 to 36,882 sq ft, cuts annual rent to $79.70/sq ft, extends term to Dec 2036.
- Lease restructuring reduces ongoing annual facility cash costs; includes $4.5M termination fee, $5.2M deferred payment, and landlord draws $6.3M letter of credit.
- Cash balance $29.8M as of Mar 31, 2026; projected operating cash runway extends well into Q1 2027.
- Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/0001193125-26-258366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/d156701d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-258366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer